The phenomenon of EMT is characterized by a series of coordinated molecular changes that enable epithelial cells to lose their junctional integrity and gain migratory and invasive properties. These alterations facilitate the spread of cancer cells beyond their original site, contributing to the aggressive nature of lung tumors. miRNAs appear to regulate a multitude of targets involved in this transition, influencing the expression of various proteins that are critical for maintaining epithelial characteristics and for promoting mesenchymal features. This intricate regulatory network is essential to understanding cancer progression and holds promise for identifying novel biomarkers for diagnostic purposes.

In prior studies, certain miRNAs have been implicated as tumor suppressors, while others function as oncogenes within the context of lung cancer. For example, miR-200 family members are often associated with maintenance of epithelial characteristics and suppression of EMT. Conversely, downregulation of these miRNAs correlates with enhanced invasive potential and metastatic behavior of lung cancer cells. This dichotomy highlights the complexity of miRNA functions, where their expression profiles can dramatically change in response to the tumor microenvironment, thereby tipping the balance between tumor suppression and progression.

Moreover, recent advances have shed light on how specific miRNAs modulate key signaling pathways instrumental in EMT. For instance, the TGF-β signaling pathway, known for its role in promoting EMT, can be influenced by miRNAs that target pivotal mediators within the pathway. Research indicates that miR-21 and miR-155 can enhance TGF-β-mediated effects, fostering a pro-EMT state that enhances tumor aggressiveness. Understanding these relationships not only provides insights into the fundamental biology of lung cancer but also opens doors to potential therapeutic interventions aiming at restoring the balance of miRNA expression.

Given the strong association of miRNAs with EMT, researchers are working to translate these findings into diagnostic tools that could detect lung cancer at earlier stages. The aberrant expression of specific miRNAs in patient samples presents an opportunity for developing non-invasive biomarkers. Liquid biopsies, which analyze circulating blood components, have shown promise in identifying miRNA signatures that correlate with tumor presence and stage. This revolutionary approach could lead to more accurate diagnoses and better monitoring of disease progression, thereby improving patient outcomes.

In addition to diagnostics, the prospect of using miRNAs in therapeutic applications is gaining traction. Several studies are investigating the feasibility of miRNA replacement therapies, where downregulated tumor-suppressive miRNAs are artificially reintroduced into cancer cells. Conversely, strategies that inhibit overexpressed oncogenic miRNAs are also being explored. Understanding the specific context in which these miRNAs function will be crucial for the successful implementation of such therapeutic strategies and for minimizing off-target effects that could arise from indiscriminate miRNA modulation.

The growing body of evidence highlighting the pivotal role of miRNAs in lung cancer underscores the urgency for continued research in this domain. The intricate relationship between miRNAs and EMT in the context of lung cancer is a rich area for exploration, with significant implications for both diagnostic and therapeutic strategies. Researchers are increasingly leveraging advanced techniques such as CRISPR/Cas9 for functional studies of miRNAs, which can elucidate their roles in the dynamics of EMT and tumorigenesis.

Moreover, the potential for miRNA-based therapies is supported by the burgeoning field of gene editing and delivery systems. Nanoparticle-assisted miRNA delivery methods are being refined to enhance the specificity and efficiency of treatment. These innovations not only foster the potential for targeted therapies but also enable the simultaneous delivery of multiple therapeutic agents, amplifying treatment efficacy while mitigating side effects. As researchers continue to bridge the gap between basic science and clinical applications, the translational potential of miRNAs as both biomarkers and therapeutic agents will become more pronounced.

In summary, the exploration of miRNAs within the context of EMT in lung cancer reveals a complex but promising landscape. The interplay between specific miRNAs and signaling pathways that facilitate EMT underscores their critical roles in cancer progression and metastasis. This understanding not only sheds light on the fundamental mechanisms driving lung cancer but also paves the way for innovative approaches to diagnosis and treatment. As the field advances, the integration of miRNA research into clinical practice holds the potential to revolutionize the management of lung cancer, ultimately improving patient prognosis and survival rates.

The impact of the findings presented is profound, as they represent a shift toward more personalized medicine in oncology. By harnessing the unique expression profiles of miRNAs in individual patients, clinicians may soon be able to tailor treatment strategies that are more effective and less harmful. As ongoing research continues to uncover the complexities of these relationships, the future of lung cancer treatment may be redefined through the incorporation of miRNAs as pivotal players in diagnosis and therapy.

Subject of Research: The impact of miRNAs on epithelial–mesenchymal transition in lung cancer and their use as diagnostic markers.

Article Title: The impact of miRNAs on epithelial–mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.

Article References:

Shi, Y., Zhao, D., Xiao, Z. et al. The impact of miRNAs on epithelial–mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers. J Cancer Res Clin Oncol 151, 252 (2025). https://doi.org/10.1007/s00432-025-06298-4

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06298-4

Keywords: miRNAs, epithelial-mesenchymal transition, lung cancer, diagnostics, biomarkers, therapeutic strategies.

MicroRNAs influence virtually all hallmarks of cancer, including unchecked proliferation, evasion of apoptosis, angiogenesis, invasiveness, and metastatic dissemination. In lung cancer, aberrant expression profiles of miRNAs disrupt the delicate balance of oncogenes and tumor suppressor genes, tipping the scale toward malignancy. For example, miR-21, a well-characterized oncogenic miRNA, is consistently upregulated in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), where it promotes cell proliferation and inhibits programmed cell death by targeting multiple tumor suppressor transcripts. Its broad impact on pathways such as PTEN/PI3K/AKT underscores its pivotal role in enhancing tumor aggressiveness and chemoresistance.

The biogenesis of miRNAs is tightly controlled through a multi-step process beginning with transcription by RNA polymerase II, generating primary miRNA (pri-miRNA) transcripts. These transcripts undergo microprocessor complex-mediated cleavage by Drosha and DGCR8 within the nucleus to produce precursor miRNAs (pre-miRNAs), which are subsequently exported to the cytoplasm. There, the RNase III enzyme Dicer processes pre-miRNAs into mature miRNA duplexes. One strand, the guide strand, is incorporated into the RNA-induced silencing complex (RISC) to execute gene regulation. Dysregulation at any stage of this pathway – whether through genetic mutations, epigenetic modifications, or altered expression of biogenesis factors – results in miRNA imbalances that contribute substantially to lung carcinogenesis.

Exosomes, the extracellular vesicles secreted by tumor cells, carry miRNAs and other molecules that modulate the tumor microenvironment and facilitate metastatic niches. These exosomal miRNAs serve as messengers, reprogramming stromal cells, promoting angiogenesis, or suppressing immune surveillance. Detection of circulating exosomal miRNAs in plasma represents a promising non-invasive biomarker platform for early lung cancer diagnosis, monitoring therapeutic response, and predicting relapse.

The dichotomous nature of miRNAs in lung cancer is exemplified by their classification as either oncogenic (oncomiRs) or tumor-suppressive miRNAs. OncomiRs, such as miR-155 and miR-10b, stimulate tumor growth, invasion, and metastasis by targeting genes that regulate apoptosis and cell adhesion. Their overexpression often correlates with poor prognosis and advanced clinical stages. Conversely, tumor-suppressor miRNAs like miR-1 and miR-7 inhibit malignant transformation by repressing oncogenic signaling pathways, including the EGFR and KRAS cascades. The frequent downregulation of these miRNAs in tumor cells removes critical restraints on cellular proliferation and survival, accelerating cancer progression.

Therapeutic exploitation of miRNA pathways is an emerging frontier in lung cancer treatment. Strategies under investigation include the use of antagomirs or locked nucleic acid (LNA) inhibitors to silence oncogenic miRNAs, thereby restoring tumor suppressor gene activity. Alternatively, synthetic miRNA mimics can replenish lost tumor-suppressive miRNAs, reinstating their regulatory functions. Delivery approaches leveraging nanoparticle systems or exosome-mimetic vesicles are being optimized to enhance specificity and minimize off-target effects, addressing critical challenges in the clinical translation of miRNA-based therapies.

In addition to their therapeutic promise, miRNAs offer unprecedented potential as biomarkers for lung cancer screening and prognosis. Profiling miRNA signatures from patient-derived biofluids enables not only earlier detection of neoplastic changes but also stratification of patients based on likely treatment responsiveness. This fits within the broader framework of precision oncology, where individualized molecular landscapes inform personalized therapeutic regimens to maximize efficacy while limiting toxicity.

Despite the exciting progress, miRNA research in lung cancer faces significant complexity. The pleiotropic nature of miRNAs, often regulating multiple target genes across diverse pathways, necessitates comprehensive mapping of miRNA-mRNA interactomes within specific cellular contexts. Furthermore, the influence of tumor heterogeneity, epigenetic background, and external environmental factors complicates the delineation of causative versus correlative roles of miRNAs in cancer biology.

Further elucidation of the mechanisms governing miRNA expression and function in lung cancer will depend on integrative approaches combining high-throughput sequencing, single-cell analysis, and functional genomics. Such studies will be instrumental in uncovering novel miRNA regulatory circuits and their interplay with canonical oncogenic signaling networks. The integration of multiomics data promises to enhance our understanding of lung tumorigenesis and identify more robust molecular targets.

In sum, microRNAs represent powerful molecular switches that intricately regulate lung cancer development and progression. By manipulating miRNA networks, researchers hope to overcome the formidable therapeutic resistance and heterogeneity that have long stymied lung cancer management. As miRNA-based diagnostics and therapeutics advance toward clinical applications, they are poised to revolutionize the landscape of lung cancer care, offering hope for improved survival and quality of life in patients afflicted with this devastating disease.

Subject of Research: Oncogenic potential and regulatory roles of microRNAs in lung cancer pathogenesis and therapy.

Article Title: Unraveling the Oncogenic Potential of microRNAs in Lung Cancer: A Narrative Review Article

News Publication Date: 19-Mar-2025

Web References:

• https://www.xiahepublishing.com/journal/csp
• http://dx.doi.org/10.14218/CSP.2025.00001

Image Credits: Mohammad Bayat, Ali Moradi

Keywords: MicroRNA, Carcinogenesis, Target mRNA, Scientific publishing, Cancer screening